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Abstract Tumour cells are known to be highly glycolytic,
thus producing high amounts of lactic acid. Monocarbox-
ylate transporters (MCTs), by promoting the efflux of the
accumulating acids, constitute one of the most important
mechanisms in the maintenance of tumour intracellular pH.
Since data concerning MCT expression in colorectal
carcinomas (CRC) are scarce and controversial, the present
study aimed to assess the expressions of MCT1, 2, and 4 in
a well characterized series of CRC and assess their role in
CRC carcinogenesis. CRC samples (126 cases) were
analyzed for MCT1, MCT2, and MCT4 immunoexpression
and findings correlated with clinico-pathological parame-
ters. Expression of all MCT isoforms in tumour cells was
significantly increased when compared to adjacent normal
epithelium. Remarkably, there was a significant gain of
membrane expression for MCT1 and MCT4 and loss of
plasma membrane expression for MCT2 in tumour cells.
Plasma membrane expression of MCT1 was directly related
to the presence of vascular invasion. This is the larger study
on MCT expression in CRC and evaluates for the first time
its clinico-pathological significance. The increased expres-
sion of these transporters suggests an important role in
CRC, which might justify their use, especially MCT1 and
MCT4, as targets in CRC drug therapy.
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Introduction
Highly proliferative cancer cells maintain a high rate of
glycolysis, producing large amounts of acids, mainly lactic
acid. Despite this fact, only the interstitial pH of tumours is
low, while the intracellular pH of tumours is either normal
or higher than that of normal tissues [3, 10]. In order to
prevent apoptosis by cellular acidosis, tumour cells increase
proton efflux through pH regulators, such as proton pumps,
sodium-proton exchangers, bicarbonate transporters, and
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monocarboxylate transporters (MCTs), which are described
to be up-regulated in tumour cells [11].
MCTs play a central role in cellular metabolism and are
essential for transport of monocarboxylates, such as lactate,
across the plasma membrane. Based on sequence homolo-
gies, 14 MCT family members were identified, although
only a few have been functionally characterized. MCT1–
MCT4 isoforms are proton symporters, which have lactate
as a common substrate, each isoform exhibiting different
biochemical properties [9]. Substrate specificity has been
associated with the tissue distribution of each transporter,
depending on their metabolic activity: MCT1 has an
ubiquitous distribution [6], while MCT2, having a high
affinity for the substrate, is found in tissues that use lactate
as a substrate (e.g., liver) [2]. MCT4, which is a low-
affinity transporter, is present in highly glycolytic tissues
(e.g., slow-twitch muscle) [4] and MCT3 is exclusively
found in the retinal pigment epithelium and in the choroid
plexus epithelium [16].
Using in vitro and ex vivo models, Wahl et al. [19]
demonstrated that MCTs are major players in the regulation
of pH in melanoma cells and proposed that MCT inhibitors
may be particularly effective against malignant melanoma.
There are also evidence for the upregulation of MCTs in
other tumours such as alveolar sarcoma of soft tissues [13],
high grade glial neoplasms [7, 15], and colorectal carcino-
mas (CRC) [12].
Lactate release from tumour cells is a common endpoint
of several metabolic alterations, raising the hypothesis of an
association with tumour progression [21]. Some evidence
support this hypothesis: low interstitial pH is associated
with the upregulation of various angiogenic molecules,
which support tumour growth, invasion, and metastasis
such as vascular endothelial growth factor [8]. Lactate
accumulation has also been associated with metastization
and lower disease-free and overall survival in squamous
cell carcinomas of the uterine cervix and head and neck
carcinomas [1, 20]. Targeting MCT activity would not only
induce apoptosis due to cellular acidosis, but would also
lead to reduction in tumour angiogenesis, invasion, and
metastasis. Thus, MCTs can constitute an attractive target
for cancer therapy.
Data concerning expression of MCTs in CRC are scarce
and controversial. While Lambert et al. [14] described a
decrease in MCT1 expression during transition to malig-
nancy, Koukourakis et al. [12] reported an increase in
MCT1 expression in tumour cells, which is supported by
the metabolic alterations induced by anaerobic glycolysis.
The latter study also assessed the expression of MCT2 and
MCT4, finding a strong cytoplasmic expression of MCT2
in cancer cells, but a weak expression of MCT4 in the
tumour environment, suggesting a minimal role of this
MCT isoform in CRC metabolic homeostasis.
Our study aimed to contribute to the elucidation of the
role of MCTs in CRC, by assessing the immunohistochem-
ical expression of the MCT isoforms 1, 2, and 4 in a large
and well characterized series of CRC and evaluating its
clinico-pathological significance.
Materials and methods
A series of formalin-fixed, paraffin-embedded tissues from
126 CRC was retrieved from the files of the Medical
School of the University of São Paulo (Brazil). Tissue
samples were analyzed for MCT1, MCT2, and MCT4
immunohistochemical expression using specific antibodies.
Comparison of MCT expression in tumour vs normal cells
was also possible since, for most cases, the same paraffin
section contained both tumour and normal colonic epithe-
lium. MCT immunohistochemical expression was correlat-
ed with the available clinico-pathological data, which
included: age, gender, tumour size, macroscopic presenta-
tion, histological type, tumour localization, depth of
invasion, vascular invasion, nodal metastasis, and TNM
classification. Normal colorectal mucosa, liver, and skeletal
muscle samples were obtained prospectively from patients
undergoing surgery: colorectal mucosa and abdominal wall
skeletal muscle were obtained from a patient with diagnosis
of diverticulosis; liver was from a patient with a diagnosis
of metastatic colon carcinoma. Informed written consent
was obtained from the individuals prior to removal of the
tissue.
Western blotting
The specificity of the antibodies used in immunohisto-
chemistry was evaluated by Western blotting. Tissue
samples from human colon, liver, and muscle were used
as positive controls for the expression of MCT1, 2, and 4,
respectively. Briefly, fresh samples were collected, ho-
mogenized in a lysis buffer and then centrifuged at 6,000
rpm, 20 min at 4°C. The supernatants were collected
and protein concentrations were determined by the
method of Lowry. Protein was separated on a 10% (w/v)
polyacrylamide gel and transferred onto a nitrocellulose
membrane (Amersham Pharmacia Biotech, Piscataway,
NJ, USA). Membranes were blocked with 1% Tween,
10% milk, and 1% bovine serum albumin in TBS for 1 h.
Membranes were then incubated overnight at 4°C with
primary polyclonal antibodies for MCT1 (AB3538P,
Chemicon International, Temecula, CA, USA), MCT2
(sc-14926, Santa Cruz Biotechnology, Santa Cruz, CA,
USA), and MCT4 (AB3316P, Chemicon International),
diluted 1:200 for MCT1 and MCT4, and 1:100 for MCT2.
Membranes were then incubated with the secondary
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antibody coupled to horseradish peroxidase (SantaCruz
Biotechnology) and bound antibodies were visualized by
chemiluminescence (Supersignal West Femto kit, Pierce,
Rockford, IL, USA).
Immunohistochemistry
Immunohistochemistry was performed according to avidin–
biotin–peroxidase complex principle (R.T.U. VECTAS-
TAIN Elite ABC Kit (Universal), Vector Laboratories,
Burlingame, CA, USA), with the primary antibodies for
MCT1, MCT2, and MCT4, used in Western blotting,
diluted 1:200. Briefly, deparaffinized and rehydrated sec-
tions were incubated in 0.3% hydrogen peroxide for
30 min, to inactivate endogenous peroxidases, and washed
in PBS. Antigen retrieval was performed by immersing
slide-mounted sections in 0.01 M citrate buffered solution
(pH 6.0) and microwaving (600 W) for 15 min then washed
in PBS. Tissue sections were then incubated with a protein
blocking solution for 20 min and incubated with the
primary antibody overnight at room temperature. Sections
were then sequentially washed in PBS and incubated
with biotinylated secondary antibody for 30 min, R.T.U.
Vectastain® Elite ABC reagent for 45 min at 37°C and
developed with 3,3′-diamino-benzidine (DAB+ Substrate
System, DakoCytomation, Carpinteria, CA, USA) for 10
min. Negative controls were performed by using the
adequate serum controls for the primary antibodies used
(N1699 and X0907, DakoCytomation, Carpinteria, CA,
USA). Normal colon, kidney, and skeletal muscle tissues
were used as positive controls for MCT1, MCT2, and
MCT4, respectively. Tissue sections were counterstained
with haematoxylin and permanently mounted.
Immunohistochemical evaluation
Sections were scored semi-quantitatively for immunoreac-
tion extension as follows: 0: 0% of immunoreactive cells; 1:
<5% of immunoreactive cells; 2: 5–50% of immunoreactive
cells; and 3: >50% of immunoreactive cells. Also, intensity
of staining was scored semi-qualitatively as 0: negative; 1:
weak; 2: intermediate; and 3: strong. Immunoreaction final
score was defined as the sum of both parameters (extension
and intensity), and grouped as negative (0), weak (2),
moderate (3), and strong (4–6). For statistical purposes,
only moderate and strong immunoreaction final scores were
considered as positive. Finally, positive plasma membrane
staining was also assessed. Evaluation of MCT immuno-
histochemical expression was performed blindly by two
independent observers and discordant cases were discussed
in a double-head microscope in order to determine a final
score.
Statistical analysis
Data were stored and analyzed using the SPSS statistical
software (version 14.0, SPSS Inc., Chicago, IL, USA). The
comparison of MCT expression between tumour and
normal cells as well as the relationship between MCT
expressions and the clinico-pathological parameters were
examined for statistical significance using Pearson’s chi-
square (χ2) test, with the threshold for significant p values
being <0.05.
Results
One hundred and twenty six cases of CRC, corresponding to
56 women and 70 men with a median age of 64 (range 24–
95), were analyzed for MCT1, MCT2, and MCT4 immuno-
histochemical expression. Western blot analyses of normal
human tissues, using the antibodies for the three MCT
isoforms, revealed protein bands around 50 kDa (Fig. 1),
consistent with the molecular weight described for these
membrane proteins [7].
Table 1 summarizes the frequency of MCT isoforms 1,
2, and 4 expressions in tumour cells and normal adjacent
epithelium. In positive cases, cytoplasmic staining was
always present while the frequency of plasma membrane
staining differed for each isoform, being more frequent for
Fig. 1 Western blotting of human tissue lysates for MCT1, 2, and 4.
Normal colon, liver, and skeletal muscle were used for MCT1, 2, and
4 detection, respectively
Table 1 Pattern of MCT staining in tumour vs normal adjacent
epithelium
Isoform n Immunoreaction Plasma membrane
Positive (%) p Positive (%) p
MCT1 <0.001 <0.001
Normal 86 34.9 9.3
Tumour 126 85.7 51.6
MCT2 0.017 0.031
Normal 84 83.3 14.3
Tumour 126 93.7 5.6
MCT4 <0.001 <0.001
Normal 89 55.1 9.0
Tumour 126 96.0 38.1
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MCT1 than for the other isoforms (51.6% vs 38.1% for
MCT4 vs 5.6% for MCT2).
MCT1 immunoexpression in tumour cells was signifi-
cantly increased, when compared to adjacent normal
epithelium (85.7% vs 34.9%, p<0.001, Table 1). Impor-
tantly, plasma membrane staining was also significantly
more frequent in tumour than in normal cells (51.6% vs
9.3%, p<0.001, Table 1). Plasma membrane expression of
MCT1 (Fig. 2) was directly related to the presence of
vascular invasion (p=0.003, Table 2).
Staining for MCT2 in tumour cells was also more
frequent than in the adjacent normal epithelium (93.7% vs
83.3%; p=0.017, Table 1). Remarkably, there was a
significant loss of plasma membrane staining in tumour
cells (14.3% vs 5.6%; p<0.001, Table 1). Although it was
possible to observe “granule” like cytoplasmic staining for
all MCT isoforms, this pattern was much more common for
MCT2 in tumour cells (Fig. 2).
MCT4 was the most frequently expressed isoform in
tumour cells, with 96% of the cases showing positive
Fig. 2 Immunohistochemical expression of MCT1, 2, and 4 in colon
carcinoma samples. Staining in tumour cells (b, d, and f: MCT1, 2,
and 4, respectively) was stronger than in the adjacent normal
epithelium (a, c, and e: MCT1, 2, and 4, respectively). MCT1 plasma
membrane staining (b) was frequently observed in tumour cells
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staining, and expression was significantly more frequent
than adjacent normal epithelium (p<0.001, Table 1). Figure 2
shows representative cases of MCT4 positive staining in
tumour cells and in adjacent normal epithelium. As
observed for MCT1, MCT4 plasma membrane staining in
tumour cells was significantly more frequent than in the
adjacent normal epithelium (p<0.001, Table 1). Assessment
of correlation between MCT4 expression and the clinico-
pathological data revealed a positive association between
MCT4 positivity and small size tumours (p=0.049, Table 3).
Discussion
Experimental evidence point at MCTs as potential targets
for cancer therapy [5, 15, 19]. However, the role of these
membrane proteins in solid tumour development and
survival is not fully understood. In the present study, we
showed an evident increase in MCT immunoexpression in
CRC cells when compared to adjacent normal epithelium.
Most importantly, we evaluated the correlation between
MCT expression in CRC and clinico-pathological data for
the first time.
Although MCT1 is described as having a ubiquitous
distribution, it appears that this MCT isoform plays an
important role in the bidirectional transport of lactate and
other short-chain fatty acids across the colonic luminal
membrane [17]. Unexpectedly, when analysing MCT
expression in the available adjacent normal epithelium, we
found that MCT1 was the least expressed isoform.
However, since these normal tissue areas are in the
surroundings of tumour cells, we cannot rule out the
possibility that these areas are under the influence of
Table 2 Assessment of correlation between MCTs membrane expression and the clinico-pathological data
Plasma membrane
Clinical data MCT1 MCT2 MCT4
n Positive (%) p Positive (%) p Positive (%) p
Tumour size (cm) 0.897 0.117 0.572
<5 53 50.9 1.9 35.8
≥5 71 52.1 8.5 40.8
Macroscopic type 0.826 0.360 0.548
Exophytic 26 46.2 0.0 30.8
Ulcerative 49 55.1 8.2 40.8
Infiltrative 12 58.3 0.0 25.0
Sessile-ulcerated 39 48.7 7.7 43.6
Histological type 0.563 0.551 0.586
Adenocarcinoma 111 50.5 5.4 38.7
Mucinous 10 60.0 10.0 30.0
Localizationa 0.261 0.474 0.923
Right colon 21 42.9 4.8 38.1
Left colon 40 45.0 2.5 40.0
Rectum 61 59.0 8.2 36.1
Invasion 0.251 0.208 0.829
T1+T2 22 40.9 0.0 36.4
T3+T4 103 54.4 6.8 38.8
Vascular invasionb 0.003 0.090 0.400
Absent 57 36.8 1.8 42.1
Present 69 63.8 8.7 34.8
Nodal metastasis 0.212 0.697 1.000
Absent 63 46.0 4.8 38.1
Present 63 57.1 6.3 38.1
TNM 0.408 0.722 0.276
Stage I 16 43.8 0.0 31.3
Stage II 35 42.9 5.7 40.0
Stage III 38 60.5 7.9 28.9
Stage IV 36 55.6 5.6 50.0
a Tumour localization was grouped as follows: right colon—cecum and ascendant colon; left colon—splenic flexure, descendant colon, sigmoid
and rectosigmoid.
b Vascular invasion includes both lymph and blood vessel invasion.
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tumour microenvironment and could show altered MCT
expression. It would then be important to further analyze
MCT expression in a series of normal colorectal samples.
Data concerning MCT1 expression in solid tumours is
scarce and there are conflicting data related to CRC [12, 14,
17]. Our immunohistochemical findings are in agreement
with the results of Koukourakis et al. [12]. Although using
different antibodies from this previous study, we were also
able to detect a high percentage of positive cases for MCT1
expression as well as MCT1 plasma membrane expression
in a high number of cases. However, these findings diverge
from previous reports, where the authors described a
decrease in MCT1 expression in CRC during transition
from normality to malignancy [14, 17]. Concerning the
clinico-pathological data, we found a significant correlation
between MCT1 plasma membrane staining and vascular
invasion. MCT1 plasma membrane localization is essential
for transporter activity and, assuming a role in the efflux of
accumulating acids, MCT1 activity would lead to extracel-
lular acidification. Then, the positive correlation between
MCT1 plasma membrane staining and vascular invasion
would be in harmony with previous reports which stated
that extracellular acidification induces invasion [10].
Data concerning MCT2 expression in solid tumour is
also limited. Contrasting with the results presented by
Lambert et al. [14], we found expression of MCT2 in both
adjacent normal epithelium and tumour cells in CRC. The
staining pattern was cytoplasmic and, in a low number of
cases, associated with the plasma membrane. Notably, we
found a significant decrease in plasma membrane staining
in tumour cells, when comparing to adjacent normal
epithelium. This finding is in agreement with the results
of Koukourakis et al. [12], who described lack of plasma
membrane expression in tumour cells but a strong cyto-
Table 3 Assessment of correlation between MCTs immunoreaction and the clinico-pathological data
Immunoreaction
Clinical data N MCT1 MCT2 MCT4
Positive (%) p Positive (%) P Positive (%) p
Tumour size (cm) 0.383 0.117 0.049
<5 53 88.7 98.1 100.0
≥5 71 83.1 91.5 93.0
Macroscopic type 0.267 0.967 0.480
Exophytic 26 76.9 92.3 100.0
Ulcerative 49 89.8 93.9 93.9
Infiltrative 12 75.0 91.7 91.7
Sessile-ulcerated 39 89.7 94.9 97.4
Histological type 0.509 0.413 0.542
Adenocarcinoma 111 87.4 93.7 96.4
Mucinous 10 80.0 100.0 100.0
Localizationa 0.586 0.714 0.900
Right colon 21 81.0 90.5 95.2
Left colon 40 82.5 95.0 95.0
Rectum 61 88.5 95.1 96.7
Invasion 0.220 0.570 0.292
T1+T2 22 77.3 90.9 100.0
T3+T4 103 87.4 94.2 95.1
Vascular invasionb 0.942 0.081 0.810
Absent 57 86.0 89.5 96.5
Present 69 85.5 97.1 95.7
Nodal metastasis 0.611 1.000 0.648
Absent 63 84.1 93.7 95.2
Present 63 87.3 93.7 96.8
TNM 0.610 0.591 0.238
Stage I 16 75.0 87.5 100.0
Stage II 35 85.7 97.1 91.4
Stage III 38 86.8 92.1 94.7
Stage IV 36 88.9 94.4 100.0
a Tumour localization was grouped as follows: right colon—cecum and ascendant colon; left colon—splenic flexure, descendant colon, sigmoid
and rectosigmoid.
b Vascular invasion includes both lymph and blood vessel invasion.
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plasmic expression. The authors hypothesized that this
cytoplasmic expression was probably associated with the
presence of MCT2 in mitochondrial membranes. Taking
into consideration the physiological role of MCT2 in the
transport of pyruvate into the mitochondria, one could
hypothesize that the highly glycolytic tumour cell would
up-regulate MCT2 in an attempt to oxidize the excess
pyruvate produced. This process would also contribute to
the “removal” of the acid accumulated in the cytoplasm.
Concerning MCT4, we found it to be the most frequently
expressed isoform in tumour cells, an expression which was
significantly increased when compared to the adjacent
normal epithelium. These findings contrast with the results
of Lambert et al. [14], who did not find MCT4 expression
in colon carcinoma and with the results of Koukourakis et
al. [12], who described weak MCT4 expression in the
tumour environment. This discrepancy could be related to
the specificity of the antibodies used. In our study, the
frequency of MCT4 staining in tumour cells was signifi-
cantly different from the adjacent normal epithelium,
which, together with the Western blot results, led us to
believe in the specificity of the antibody used. We also
found an increase in MCT4 plasma membrane staining in
tumour cells when comparing with the adjacent normal
epithelium. This fact supports the hypothesis that MCTs are
important in the efflux of accumulated acids in tumour
cells, specially MCT4 which, due to its low affinity for
lactate, would be important in highly glycolytic cells [4].
We can thus postulate that MCT4 presence in the plasma
membrane will allow continuous glycolytic rate (by
“removing” the end product), prevention of apoptosis due
to intracellular acidification and contribution to cancer cell
survival. Evaluation of the correlation between MCT4
expression and clinico-pathological data revealed positive
associations with tumour size, however the correlation is
weak (p=0.049). Nevertheless, assuming that the glycolysis
rate in smaller tumours is higher than in bigger tumours
[18], and considering the role of MCT4 in lactate efflux, it
is understandable that MCT4 activity would not be so
crucial in bigger-sized tumours.
One of the most notable findings in this study was the
significant gain of MCT1 and MCT4 plasma membrane
expression and loss of MCT2 plasma membrane expression
in cancer cells. Since MCTs need to be in the plasma
membrane in order to export the accumulating acids in
highly glycolytic cells, and taking into consideration the
substrate affinities of the different isoforms, MCT1 and
MCT4 expression in the membrane is in agreement with the
metabolic alterations observed in cancer cells. On the other
hand, MCT2, which is involved in the uptake of mono-
carboxylates into the cells in normal cell metabolism [2],
does not appear to have an important role in highly
glycolytic cancer cells.
This is the most comprehensive study on MCT expression
in CRC and the above findings point to MCTs, specially
MCT1 andMCT4, as playing an important role in CRC.MCT
aberrant expression might justify future studies using these
proteins as targets in CRC drug therapy. So far, however, the
level of human toxicity and efficacy of the known MCT
inhibitors are not currently known [7] and the search for
effective and safe inhibitors would be of great value.
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